Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...

This rare genetic disease requires millions of dollars to treat. A single dose of the gene therapy drug called Zolgensma, which is enough to treat the disease, can cost up to USD 2 million. In less ...

Concern about the safety of gene therapies has been thrust into the spotlight again with the news that two patients treated with Novartis' spinal muscular atrophy (SMA) treatment Zolgensma died as ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Novartis’ troubles over the Zolgensma data manipulation incident show no sign of lessening. The company is on the defensive again after it emerged a senior manager sold almost $1 million worth ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved ...

Over 95% of babies now diagnosed with SMA are treated with Zolgensma gene therapy, per Daniel Grant, vice president for ...

There are three types of treatment for SMA patients: gene therapy Zolgensma, which costs ₹17 crore, and two other drugs — Nusinersen (₹87 lakh) and Risdiplam (₹6.2 lakh per bottle). In a statement, ...